MLKL and prostate carcinoma: When prostate cancer cells were treated with the MLKL inhibitor NSA, the inhibition of proliferation induced by overexpression of RIP3 stopped (Figure 6I), indicating that necroptosis is the main cause of tumor proliferation inhibition.